prof. dr. M.C. (Monique) Minnema

prof. dr. M.C. (Monique) Minnema

Full Professor
prof. dr. M.C. (Monique) Minnema
  • Department of Hematology



Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and was appointed full professor in 2019. She is specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis  like Multiple Myeloma and AL amyloidosis, and Waldenstrom Macroglobulinemia. Prof Minnema is author on several national and internatonial quidelines on the diagnosis and treatment of these diseases.
She is head supervisor of the hematology clinical research team, the hematology biobank and the European expertise reference network (ERN) malignant hematology of the UMC Utrecht. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias. 

Prof Dr Minnema is an active member of the HOVON working parties for Multiple
Myeloma, Lymphoma, IEC and the vice president of the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Examples of her work are the HOVON 104 trial for patients with AL amyloidosis first line treatment, the clinical studies with the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and newly diagnosed AL amyloidosis and anti CD19 CAR T cells in relapsed Lymphoma.
Her translational research focuses on 3D models to predict response to therapy and the use of combined immunotherapy for relapsed multiple myeloma.

She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016, and is co initiator of the yearly Immune Effector Cell and the Systemic Amyloidosis symposia. 

Side Activities


  • NIV
  • NVvH
  • ASH
  • EHA

Board activities:

  • 2006 onwards: member HOVON working party multiple myeloma, lymphoma, LLPC and Immune Effector Cell (IEC)
  • 2014 onwards: board member Nederlandse Vereniging van Hematologie
  • 2019 onwards: program committee yearly Symposium on Systemic Amyloidosis and Symposium IEC
  • 2019 onwards: Women in Lymphoma steering committee (international)
  • 2021-2022: lid ZonMw beoordelingscommissie
  • 2022 onwards: lid KWF beoordelingscommissie Ontwikkeling en Implementatie
  • May – Nov 2022: lid structuurcommissie van de leerstoel ‘Antistoftherapie’ 
  • May 2022 onwards: bestuurslid HOVON Myeloom WG 
  • August 2022 onwards: member MPE’s Medical Advisory Committee
  • Sept 2022 onwards: member steering committee Aquarius trial
  • Sept 2022 onwards: member IWMF Scientific Advisory Sub-Committee on the Waldenstrom’s Macroglobulinemia (WM) Global Awareness Building Initiative
  • Oct 2022 onwards: Member International Myeloma Working Group 

Conflicts of interest:

  • 2022: paid to institution, consultancy and speakers bureau Janssen Cilag, paid to institution, consultancy GSK, paid to institution, consultancy BMS, paid to institution, consultancy CDR-Life. 
  • 2021: paid to institution, speakers bureau Medscape, paid to institution consultancy Janssen Cilag, paid to institution, speakers bureau Pfizer.
  • 2020: paid to institution, speakers bureau Celgene, paid to institution consultancy Janssen Cilag
  • 2019: paid to institution, speakers bureau Gilead, paid to institution consultancy Alnylam, paid to person; Hospitality Celgene
  • 2018: paid to institution, speakers bureau Roche, Gilead, Celgene, paid to institution consultancy Takeda, Janssen Cilag, paid to person; Hospitality Celgene

Stichting Transparantieregister Zorg - Home, BIG 59043578201

Research Output (169)

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Shah Bijal D, Ghobadi Armin, Oluwole Olalekan O, Logan Aaron C, Boissel Nicolas, Cassaday Ryan D, Leguay Thibaut, Bishop Michael R, Topp Max S, Tzachanis Dimitrios, O'Dwyer Kristen M, Arellano Martha L, Lin Yi, Baer Maria R, Schiller Gary J, Park Jae H, Subklewe Marion, Abedi Mehrdad, Minnema Monique C, Wierda William G, DeAngelo Daniel J, Stiff Patrick, Jeyakumar Deepa, Dong Jinghui, Adhikary Sabina, Zhou Lang, Schuberth Petra C, Faghmous Imi, Masouleh Behzad Kharabi, Houot Roch 10 Dec 2022, In: Journal of hematology & oncology. 15

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Chari Ajai, Minnema Monique C, Berdeja Jesus G, Oriol Albert, van de Donk Niels W C J, Rodríguez-Otero Paula, Askari Elham, Mateos María-Victoria, Costa Luciano J, Caers Jo, Verona Raluca, Girgis Suzette, Yang Shiyi, Goldsmith Rachel B, Yao Xiang, Pillarisetti Kodandaram, Hilder Brandi W, Russell Jeffery, Goldberg Jenna D, Krishnan Amrita 10 Dec 2022, In: The New England journal of medicine. 387 , p. 2232-2244 13 p.

Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies

van de Mortel Max, D'Sa Shirley, Vrancken Alexander, Notermans Nicolette C, Vos Josephine, Minnema M Dec 2022, In: Hemato. 3 , p. 663-688

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis:Phase 3 ANDROMEDA Trial

Minnema Monique C, Dispenzieri Angela, Merlini Giampaolo, Comenzo Raymond L, Kastritis Efstathios, Wechalekar Ashutosh D, Grogan Martha, Witteles Ronald, Ruberg Frederick L, Maurer Mathew S, Tran NamPhuong, Qin Xiang, Vasey Sandra Y, Weiss Brendan M, Vermeulen Jessica, Jaccard Arnaud Nov 2022, In: J AM Coll Cardiol CardioOnc. 4 , p. 474-487 14 p.

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia

Amaador Karima, Kersten Marie J, Minnema Monique C, Vos Josephine M I 25 Oct 2022, In: Leukemia & lymphoma. 64 , p. 30-41 12 p.

Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA:the CASSIOPET study

Kraeber-Bodéré Françoise, Zweegman Sonja, Perrot Aurore, Hulin Cyrille, Caillot Denis, Facon Thierry, Leleu Xavier, Belhadj Karim, Itti Emmanuel, Karlin Lionel, Bailly Clément, Levin Mark-David, Minnema Monique C, Jamet Bastien, Bodet-Milin Caroline, De Keizer Bart, Béné Marie C, Avet-Loiseau Hervé, Sonneveld Pieter, Pei Lixia, Rigat Fabio, De Boer Carla, Vermeulen Jessica, Kampfenkel Tobias, Lambert Jérôme, Moreau Philippe 20 Oct 2022, In: Haematologica. 108 , p. 621-626 6 p.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001):a multicentre, multicohort, open-label, phase 1/2 trial

Lonial Sagar, Popat Rakesh, Hulin Cyrille, Jagannath Sundar, Oriol Albert, Richardson Paul G, Facon Thierry, Weisel Katja, Larsen Jeremy T, Minnema Monique C, Abdallah Al-Ola, Badros Ashraf Z, Knop Stefan, Stadtmauer Edward A, Cheng Yiming, Amatangelo Michael, Chen Min, Nguyen Tuong Vi, Amin Alpesh, Peluso Teresa, van de Donk Niels W C J 6 Oct 2022, In: Lancet haematology. 9 , p. e822-e832

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Sonneveld Pieter, Zweegman Sonja, Cavo Michele, Nasserinejad Kazem, Broijl Annemiek, Troia Rosella, Pour Ludek, Croockewit Sandra, Corradini Paolo, Patriarca Francesca, Wu Kalung, Droogendijk Jolanda, Bos Gerard, Hajek Roman, Teresa Petrucci Maria, Ypma Paula, Zojer Nicholas, Minnema Monique C, Boccadoro Mario Oct 2022, In: HemaSphere. 6 , p. 1-8

Patient preferences regarding treatment options for Waldenström's macroglobulinemia:A discrete choice experiment

Amaador Karima, Nieuwkerk Pythia T, Minnema Monique C, Kersten Marie José, Vos Josephine M I 26 Jul 2022, In: Cancer Medicine. 12 , p. 3376-3386 11 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet